GOREISAN for Heart Failure (GOREISAN-HF) Trial

Summary

The objective of the GOREISAN-HF trial is to assess the effect of the administration of Goreisan (TJ-17) plus standard therapy compared to standard therapy alone on the improvement rate of cardiac edema and clinical outcomes in worsening congestive heart failure with volume overload.

Timeline

Start

2021-01-19

Primary completion

2027-12-31

Completion

2027-12-31

Publications

• Yaku H, Kato T, Morimoto T, Kaneda K, Nishikawa R, Kitai T, Inuzuka Y, Tamaki Y, Yamazaki T, Kitamura J, Ezaki H, Nagao K, Yamamoto H, Isotani A, Takeshi A, Izumi C, Sato Y, Nakagawa Y, Matoba S, Sakata Y, Kuwahara K, Kimura T; GOREISAN-HF trial Investigators. Rationale and study design of the GOREISAN for heart failure (GOREISAN-HF) trial: A randomized clinical trial. Am Heart J. 2023 Jun;260:18-25. doi: 10.1016/j.ahj.2023.02.013. Epub 2023 Feb 24.

Drugs

Indications